Stent Thrombosis: Incidence, Predictors and New Technologies
Table 6
Ongoing studies assessing pharmacogenomics and antiplatelet therapy.
Study
Number of patients
Patient population
Therapy
Primary endpoint
GIFT
NA
All-comers undergoing PCI
Tailored clopidogrel versus standard clopidogrel according to platelet reactivity and genetic type
Residual platelet activity
TARGET-PCI
1,500
Nonemergent PCI
Tailored with clopidogrel and prasugrel to results of platelet reactivity and genetic type
MACE
CLOVIS-2
120
Post-MI
Clopidogrel 300 mg versus Clopidogrel 600 mg in 2 genetic CYP2C19 types
Inhibition of residual platelet activity 6 hours following clopidogrel
PREDICT
42
Stable CAD
Those with high residual platelet activity on clopidogrel and genotyped for CYP2C19 treated with double dose clopidogrel
Change in residual platelet activity
GeCCO
14,600
Recent ACS
Genotype-guided comparison of clopidogrel in extensive metabolizers and prasugrel
Cardiovascular death, nonfatal MI, or nonfatal stroke
GIFT: Genotype Information and Functional Testing; TARGET-PCI: Thrombocyte Activity Reassessment and Genotyping for PCI; CLOVIS-2: Clopidogrel and response Variability Investigation Study 2; PREDICT: Pilot Study on the Effect of High Clopidogrel Maintenance Dosing; GeCCO: Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study; PCI: percutaneous coronary intervention; MI: myocardial infarction; CAD: coronary artery disease; ACS: acute coronary syndrome; MACE: major adverse cardiovascular event.
